This was reported by TASS with reference to the order of the Russian government.
The document comes into force in two months.
"Oncaspar" is an expensive drug for the treatment of children with acute lymphoblastic leukemia.
The drug is produced in France and is not registered in Russia.
There are no analogues of the drug in Russia.
Earlier, Roszdravnadzor announced that the cost of drugs from the list of vital ones increased in Russia by 1.8% over the 11 months of this year, which indicates a stable market situation.